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BACKGROUND: Cysteamine has been demonstrated as potentially effective in
numerous animal models of Huntington's disease.
METHODS: Ninety-six patients with early-stage Huntington's disease were
randomized to 1200 mg delayed-release cysteamine bitartrate or placebo daily for
18 months. The primary end point was the change from baseline in the UHDRS
Total Motor Score. A linear mixed-effects model for repeated measures was used to
assess treatment effect, expressed as the least-squares mean difference of
cysteamine minus placebo, with negative values indicating less deterioration
relative to placebo.
RESULTS: At 18 months, the treatment effect was not statistically significant -
least-squares mean difference, -1.5 ± 1.71 (P = 0.385) - although this did represent
less mean deterioration from baseline for the treated group relative to placebo.
Treatment with cysteamine was safe and well tolerated.
CONCLUSIONS: Efficacy of cysteamine was not demonstrated in this study
population of patients with Huntington's disease. Post hoc analyses indicate the
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